FOCUS ISSUE: CARDIAC INTERVENTION: SIROLIMUS-PACLITAXEL COMPARISON
Clinical Outcomes for Sirolimus-Eluting Stents and Polymer-Coated Paclitaxel-Eluting Stents in Daily Practice
Results From a Large Multicenter Registry
Francesco Saia, MD, PhD*,*,
Giancarlo Piovaccari, MD ,
Antonio Manari, MD ,
Andrea Santarelli, MD,
Alberto Benassi, MD ,
Enrico Aurier, MD||,
Pietro Sangiorgio, MD¶,
Fabio Tarantino, MD#,
Giuseppe Geraci, MD**,
Giuseppe Vecchi, MD,
Paolo Guastaroba, MSc,
Roberto Grilli, MD and
Antonio Marzocchi, MD*
* Istituto di Cardiologia, Università di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy
Unità Operativa di Cardiologia, Ospedale degli Infermi, Rimini, Italy
Unità Operativa di Cardiologia Interventistica, Ospedale S. Maria Nuova, Reggio Emilia, Italy
Laboratorio di Emodinamica, Hesperia Hospital, Modena, Italy
|| Divisione di Cardiologia, Ospedale Maggiore, Parma, Italy
¶ Divisione di Cardiologia, Ospedale Maggiore, Bologna, Italy
# Laboratorio di Emodinamica, Ospedale Morgagni, Forlì, Italy
** Laboratorio di Emodinamica, Policlinico di Modena, Modena, Italy
Unità Operativa di Cardiologia—Centro Interventistico, Ospedale S. Maria delle Croci, Ravenna, Italy
Agenzia Sanitaria Regionale Regione Emilia-Romagna, Bologna, Italy.
Manuscript received January 6, 2006;
revised manuscript received March 23, 2006,
accepted March 28, 2006.
* Reprint requests and correspondence: Dr. Francesco Saia, Catheterization Laboratory, Institute of Cardiology—University of Bologna, Policlinico S.Orsola-Malpighi (Pad 21), Via Massarenti, 9, 40138 Bologna, Italy. (Email: francescosaia{at}hotmail.com).
OBJECTIVES: We compared the clinical outcome of sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in a real-world scenario.
BACKGROUND: In selected patients, SES has been associated with lower late luminal loss than PES. Whether this emerging biological difference could translate into different clinical efficacy in daily practice is presently unknown.
METHODS: This analysis included 1,676 consecutive patients with de novo coronary lesions treated solely with drug-eluting stents (SES = 992; PES = 684). All patients were enrolled in a dynamic prospective registry comprising 13 hospitals. We assessed the cumulative incidence of major adverse cardiac events (MACE), defined as death, myocardial infarction (MI), and target vessel revascularization (TVR) during follow-up.
RESULTS: Overall, 29% of the patients had diabetes, 23% had prior MI, and 9% had poor left ventricular function. ST-segment elevation MI was diagnosed at admission in 12%. Multivessel intervention was performed in 16%. At 1-year follow-up, SES was associated with a reduced incidence of MACE (9.2% SES vs. 14.1% PES; p = 0.007) and TVR (5.0% SES vs. 10.0% PES; p = 0.0008) compared to PES. A propensity analysis with many clinical and angiographic variables was carried out to adjust for baseline differences. In this analysis, SES was associated with a 44% risk reduction of MACE (hazard ratio 0.56, 95% confidence interval 0.39 to 0.78) and a 55% reduction of TVR (hazard ratio 0.45, 95% confidence interval 0.29 to 0.70). This result was consistent across most subgroups tested. Similar rates of death and MI were observed in the 2 treatment groups.
CONCLUSIONS: In this large real-world population, SES improved 1-year clinical results as compared to PES.
|
Abbreviations and Acronyms
| | MACE = major adverse cardiac events | | MI = (acute) myocardial infarction | | PCI = percutaneous coronary intervention | | PES = paclitaxel-eluting stent | | REAL = REgistro regionale AngiopLastiche dell’Emilia-Romagna | | SES = sirolimus-eluting stent | | TLR = target lesion revascularization | | TVR = target vessel revascularization |
|
This article has been cited by other articles:
|
|
|
|
 
P. Garg, D. J. Cohen, T. Gaziano, and L. Mauri
Balancing the Risks of Restenosis and Stent Thrombosis in Bare-Metal Versus Drug-Eluting Stents: Results of a Decision Analytic Model
J. Am. Coll. Cardiol.,
May 13, 2008;
51(19):
1844 - 1853.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Kip, K. Hollabaugh, O. C. Marroquin, and D. O. Williams
The Problem With Composite End Points in Cardiovascular Studies The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention.
J. Am. Coll. Cardiol.,
February 19, 2008;
51(7):
701 - 707.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Kirtane, S. G. Ellis, K. D. Dawkins, A. Colombo, E. Grube, J. J. Popma, M. Fahy, M. B. Leon, J. W. Moses, R. Mehran, et al.
Paclitaxel-Eluting Coronary Stents in Patients With Diabetes Mellitus Pooled Analysis From 5 Randomized Trials.
J. Am. Coll. Cardiol.,
February 19, 2008;
51(7):
708 - 715.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Tomai, B. Reimers, L. De Luca, A. R. Galassi, A. Gaspardone, A. S. Ghini, V. Ferrero, L. Favero, G. Gioffre, F. Prati, et al.
Head-to-Head Comparison of Sirolimus- and Paclitaxel-Eluting Stent in the Same Diabetic Patient With Multiple Coronary Artery Lesions: A prospective, randomized, multicenter study
Diabetes Care,
January 1, 2008;
31(1):
15 - 19.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. M M Pires, D. Eefting, M. R de Vries, P. H A Quax, and J W. Jukema
Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries
Heart,
August 1, 2007;
93(8):
922 - 927.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol.,
July 17, 2007;
50(3):
270 - 285.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, J. Narula, D. J. Sahn, et al.
Highlights of the Year in JACC 2006
J. Am. Coll. Cardiol.,
January 30, 2007;
49(4):
509 - 527.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. O. Williams, J. D. Abbott, K. E. Kip, and for the DEScover Investigators
Outcomes of 6906 Patients Undergoing Percutaneous Coronary Intervention in the Era of Drug-Eluting Stents: Report of the DEScover Registry
Circulation,
November 14, 2006;
114(20):
2154 - 2162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Another Front in the Drug-Eluting Stent Battle
Journal Watch Cardiology,
November 1, 2006;
2006(1101):
4 - 4.
[Full Text]
|
|
|
|
